Suchergebnisse - "Kishi, Haruka"

PubPharm (16)

1

Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes : insights from the randomized PROTECT trial

enthalten in: Hypertension research : official journal of the Japanese Society of Hypertension | 2024

von Saito, Y. | Tanaka, A. | Imai, T. | +108

CommentIn: Hypertens Res. 2024 Jan 5;:. - PMID 38182906

2

Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor

enthalten in: Journal of diabetes and its complications | 2024

von Wakamatsu, S. | Jojima, T. | Hashiguchi, M. | +8

3

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes : sub-analysis of the PROTECT study

enthalten in: Cardiovascular diabetology | 2023

von Kishimoto, S. | Higashi, Y. | Imai, T. | +107

4

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes : a multicenter, randomized, controlled trial

enthalten in: European heart journal. Cardiovascular pharmacotherapy | 2023

von Tanaka, A. | Sata, M. | Okada, Y. | +113

5

Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice

enthalten in: International journal of molecular sciences | 2022

von Kishi, H. | Usui, I. | Jojima, T. | +9

6

A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation

enthalten in: Clinical case reports | 2020

von Kishi, H. | Jojima, T. | Kogai, T. | +13

7

A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation

enthalten in: Clinical Case Reports | 2020

von Kishi, H. | Jojima, T. | Kogai, T. | +13

8

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

enthalten in: International journal of clinical practice | 2019

von Aso, Y. | Kato, K. | Sakurai, S. | +7

9

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

enthalten in: International Journal of Clinical Practice | 2019

von Aso, Y. | Kato, K. | Sakurai, S. | +7

10

Left-handedly curved DNA regulates accessibility to cis-DNA elements in chromatin

enthalten in: Nucleic acids research | 2013

von Nishikawa, J. | Amano, M. | Fukue, Y. | +5